Search Results
Search for other papers by Annalisa Blasetti in
Google Scholar
PubMed
Search for other papers by Valeria Castorani in
Google Scholar
PubMed
Search for other papers by Nella Polidori in
Google Scholar
PubMed
Search for other papers by Ilaria Mascioli in
Google Scholar
PubMed
Search for other papers by Francesco Chiarelli in
Google Scholar
PubMed
Search for other papers by Cosimo Giannini in
Google Scholar
PubMed
Introduction Type 1 diabetes (T1D) and other chronic diseases are well recognized to adversely affect linear growth in childhood. Indeed, early studies have shown that suboptimal glycemic control and longer disease duration can impair
Search for other papers by Wenjun Long in
Google Scholar
PubMed
Search for other papers by Tuo Zhou in
Google Scholar
PubMed
Search for other papers by Xiuping Xuan in
Google Scholar
PubMed
Search for other papers by Qiuli Cao in
Google Scholar
PubMed
Search for other papers by Zuojie Luo in
Google Scholar
PubMed
Search for other papers by Yingfen Qin in
Google Scholar
PubMed
Search for other papers by Qin Ning in
Google Scholar
PubMed
Search for other papers by Xiaoping Luo in
Google Scholar
PubMed
Search for other papers by Xuemei Xie in
Google Scholar
PubMed
), cardiovascular and cerebrovascular diseases, etc. ( 1 , 2 , 3 ). Intrauterine growth restriction (IUGR), caused by detrimental intrauterine environment, affects 23.8% or approximately 30 million newborns per year globally ( 4 ). In a proper environment, most of
Search for other papers by Mohamed Asrih in
Google Scholar
PubMed
Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland
Diabetes Center, Faculty of Medicine, University of Geneva, Geneva, Switzerland
Search for other papers by Flore Sinturel in
Google Scholar
PubMed
Search for other papers by Richard Dubos in
Google Scholar
PubMed
Search for other papers by Idris Guessous in
Google Scholar
PubMed
Diabetes Center, Faculty of Medicine, University of Geneva, Geneva, Switzerland
Search for other papers by Zoltan Pataky in
Google Scholar
PubMed
Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland
Diabetes Center, Faculty of Medicine, University of Geneva, Geneva, Switzerland
Search for other papers by Charna Dibner in
Google Scholar
PubMed
Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland
Diabetes Center, Faculty of Medicine, University of Geneva, Geneva, Switzerland
Search for other papers by François R Jornayvaz in
Google Scholar
PubMed
Diabetes Center, Faculty of Medicine, University of Geneva, Geneva, Switzerland
Search for other papers by Karim Gariani in
Google Scholar
PubMed
homeostasis and T2D risk have already been reported ( 5 ), considering sex appears to be of particular importance when searching for biomarkers of metabolic disorders. Growth differentiation factor-15 (GDF15), a member of the transforming growth factor
Search for other papers by Giovanni Fanni in
Google Scholar
PubMed
Search for other papers by Petros Katsogiannos in
Google Scholar
PubMed
Search for other papers by Bipasha Nandi Jui in
Google Scholar
PubMed
Search for other papers by Magnus Sundbom in
Google Scholar
PubMed
Search for other papers by Susanne Hetty in
Google Scholar
PubMed
Search for other papers by Maria J Pereira in
Google Scholar
PubMed
Search for other papers by Jan W Eriksson in
Google Scholar
PubMed
and pancreatic islets but also of others produced by the pituitary and adrenal glands. Therefore, in this study, we assess growth hormone (GH), ACTH, and cortisol levels, which are largely unexplored in this context. Herein, we report exploratory post
Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Search for other papers by Peter Wolf in
Google Scholar
PubMed
Search for other papers by Alexandre Dormoy in
Google Scholar
PubMed
Search for other papers by Luigi Maione in
Google Scholar
PubMed
Search for other papers by Sylvie Salenave in
Google Scholar
PubMed
Search for other papers by Jacques Young in
Google Scholar
PubMed
Search for other papers by Peter Kamenický in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
Introduction Acromegaly results in a clinical syndrome following increased serum concentrations of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). If not adequately treated, GH excess is associated with increased morbidity and
Search for other papers by Clemens Kamrath in
Google Scholar
PubMed
Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany
Search for other papers by Alexander Eckert in
Google Scholar
PubMed
Search for other papers by Birgit Rami-Merhar in
Google Scholar
PubMed
Search for other papers by Sebastian Kummer in
Google Scholar
PubMed
Search for other papers by Martin Wabitsch in
Google Scholar
PubMed
Search for other papers by Katharina Laubner in
Google Scholar
PubMed
Search for other papers by Florian Kopp in
Google Scholar
PubMed
Search for other papers by Silvia Müther in
Google Scholar
PubMed
Search for other papers by Steffen Mühldorfer in
Google Scholar
PubMed
Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany
Search for other papers by Reinhard W Holl in
Google Scholar
PubMed
analog of leptin, but none of the other 17 patients with the other LD types ( Table 4 ). One patient documented with RMS was treated with recombinant human insulin-like growth factor 1 (rhIGF1). Table 5 Overview of treatments in patients with
Search for other papers by Xianghe Chen in
Google Scholar
PubMed
Search for other papers by Xinyu Zeng in
Google Scholar
PubMed
Search for other papers by Xiao Qiu in
Google Scholar
PubMed
Search for other papers by Chi Liu in
Google Scholar
PubMed
Search for other papers by Pengcheng Lu in
Google Scholar
PubMed
Search for other papers by Ziming Shen in
Google Scholar
PubMed
Search for other papers by Xiangxiang Zhou in
Google Scholar
PubMed
Search for other papers by Kang Yang in
Google Scholar
PubMed
that the diminished expression of Sirt1 would contribute to the higher occurrence of renal interstitial fibrosis in T2DM. That is related to the fact that the downregulation of Sirt1 expression can activate the transforming growth factor β1 (TGF-β1
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Xiaohui Qi in
Google Scholar
PubMed
Search for other papers by Ping He in
Google Scholar
PubMed
Search for other papers by Huayan Yao in
Google Scholar
PubMed
Search for other papers by Huanhuan Sun in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Jiying Qi in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Min Cao in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Bin Cui in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Guang Ning in
Google Scholar
PubMed
shown that insulin and insulin-like growth factor (IGF) are involved in the development and progression of malignancies ( 9 , 10 ). Insulin has been reported to be associated with an increased risk of several cancer sites, such as the liver, pancreas
Mary & Dick Allen Diabetes Center at Hoag Hospital, Newport Beach, California, USA
Search for other papers by David Q Pham in
Google Scholar
PubMed
Search for other papers by Ashley Thorsell in
Google Scholar
PubMed
Search for other papers by Kristin Castorino in
Google Scholar
PubMed
Search for other papers by Brandon Cobb in
Google Scholar
PubMed
arms of the CONCEPTT? (iii) are there associations between maternal glucose metrics and maternal and neonatal outcomes? (iv) is maternal fear of hypoglycemia a factor in glucose control? (v) What tools are best for assessing neonatal growth and fetal
Search for other papers by Svjatoslavs Kistkins in
Google Scholar
PubMed
Search for other papers by Othmar Moser in
Google Scholar
PubMed
Search for other papers by Vitālijs Ankudovičs in
Google Scholar
PubMed
Search for other papers by Dmitrijs Blizņuks in
Google Scholar
PubMed
Search for other papers by Timurs Mihailovs in
Google Scholar
PubMed
Search for other papers by Sergejs Lobanovs in
Google Scholar
PubMed
Search for other papers by Harald Sourij in
Google Scholar
PubMed
Search for other papers by Andreas F H Pfeiffer in
Google Scholar
PubMed
Faculty of Medicine, University of Latvia, Riga, Latvia
Search for other papers by Valdis Pīrāgs in
Google Scholar
PubMed
compared to normal weight people with diabetes ( 4 ). With mounting cases of diabesity, especially among geriatric patients, the obesity and diabetes treatment markets are estimated to witness significant growth. The diabesity pandemic is spurred by rapidly